News | December 01, 2024
Dr. Reddy's launches Toripalimab in India
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The product will be marketed by Dr. Reddy's
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated
